March 06, 2023 — 06:14 am EST
(RTTNews) – Adaptimmune Therapeutics plc (ADAP) and TCR² Therapeutics Inc. (TCRR) have entered into a definitive agreement under which Adaptimmune will combine with TCR² in an all-stock deal. TCR² stockholders will receive 1.5117 Adaptimmune ADS for each TCR² share. Adaptimmune shareholders will own approximately 75% of the combined company and TCR² stockholders will own approximately 25% of the combined company.
It is anticipated that the combined company’s cash runway will extend into 2026. The combined company is expected to continue to trade on the Nasdaq Stock Market under the symbol ADAP.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT’s Financial Newswire is relied upon by some of the world’s largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
Source : Nasdaq